Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN CHILDREN
Autore:
HOERNLE EH; REID TE;
Indirizzi:
COOK CTY HOSP,DEPT CLIN PHARM SERV,SUITE 552,1900 W POLK ST CHICAGO IL 60612 UNIV S CAROLINA,COLL PHARM COLUMBIA SC 29208 UNIV S CAROLINA,SCH MED,CHILDRENS IMMUNOL CTR S CAROLINA,DEPT PEDIAT COLUMBIA SC 29208
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 9, volume: 52, anno: 1995,
pagine: 961 - 979
SICI:
1079-2082(1995)52:9<961:HIIC>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY-SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; ZIDOVUDINE THERAPY; HIV-INFECTION; CONTINUOUS-INFUSION; ORAL ZIDOVUDINE; AEROSOLIZED PENTAMIDINE; PEDIATRIC-PATIENTS; ADVERSE REACTIONS;
Keywords:
ANTIINFECTIVE AGENTS; ANTIVIRALS; DAPSONE; DIDANOSINE; DOSAGE SCHEDULES; IMMUNIZATION; LAMIVUDINE; NEVIRAPINE; PEDIATRICS; PENTAMIDINE; PNEUMONIA; STAVUDINE; SULFAMETHOXAZOLE; SULFONAMIDES; TRIMETHOPRIM; ZIDOVUDINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
137
Recensione:
Indirizzi per estratti:
Citazione:
E.H. Hoernle e T.E. Reid, "HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN CHILDREN", American journal of health-system pharmacy, 52(9), 1995, pp. 961-979

Abstract

The transmission, diagnosis, and clinical manifestations of human immunodeficiency virus (HIV) infection in children up to 13 years of age are reviewed, and maintenance and prophylactic drug therapies for these patients are discussed.HIV can be transmitted from mother to infant in utero, during delivery, or through breast milk. Perinatal transmission accounts for almost 90% of all pediatric HIV infections. HIV infection can be diagnosed with HIV culturing, polymerase chain reaction testing, the enzyme-linked immunosorbent assay, the Western blot antibody assay, or the p24 core-antigen assay. Testing should begin as soon as possible after the atrisk child reaches one month of age. CD4+ lymphocyte counts are also used in diagnosis and monitoring. The median ageat diagnosis of AIDS in children with perinatally acquired HN infection is 12-24 months. Among the many possible clinical features are Pneumocystis carinii pneumonia (PCP), cytomegalovirus infection, failure to thrive, encephalopathy, recurrent bacterial infection, thrush, lymphoid interstitial pneumonitis, lymphadenopathy, pancreatis, hepatitis, anemia, and thrombocytopenia. Zidovudine is considered the drug of choice for initial therapy in HIV-infected children and is indicated for asymptomatic infection, early symptomatic disease, and advanced disease. However, new research is questioning the role of zidovudine monotherapy. Didanosine is the only agent with FDA-approved labeling for use as second-line therapy in children who do not respond to or become resistant to zidovudine. Agents under investigation for pediatric use arezalcitabine, stavudine, lamivudine, and nevirapine. Drug combinations, such as zidovudine plus didanosine, are also being examined. Zidovudine appears to reduce the rate of maternal transmission of HIV. Agentsused prophylactically against PCP in children are trimethoprim-sulfamethoxazole, dapsone, and inhaled or i.v. pentamidine. HIV-infected children should also receive prophylaxis against recurrent bacterial infections. The standard pediatric immunization schedule is used, but inactivated injectable poliovirus vaccine must be given instead of the live oral vaccine.Zidovudine remains the first-line agent for treating HIV infection in children. Alternatives are available for those who do not respond to zidovudine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 16:01:17